Compugen Ltd. (Exact Name of Registrant As Specified in Its Charter and Translation of Registrant's Name Into English) ______
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
2019 Breakthrough Summit Co-Host Committee 2019 Breakthrough
2019 Breakthrough Summit Co-Host Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Stock and Other Patents, Royalties, Travel, Speakers' Expert Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Research Funding Other Intellectual Accommodations, Other Bureau Testimony Interests Property Expenses Dae Ho Lee Abbvie, AstraZeneca/MedImmune, Boehringer ST Cube Ingelheim, Bristol-Myers Squibb, Chong Kun Dang Pharmaceutical, CJ Healthcare, Janssen, Lilly, Merck, MSD, Mundipharma, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Samyang, ST Cube, Takeda Ekaphop Amgen, AstraZeneca, Boehringer Ingelheim, Bristol- AstraZeneca, MSD, Sirachainan Myers Squibb, Diethelm Keller Logistics, LF Asia, Pfizer Merck, MSD, Mundipharma, Roche, Sanofi/Aventis Lillian L. Siu Agios (I) Agios (I) AstraZeneca/MedImmune, Loxo, Merck, Amgen (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), MorphoSys, Roche, Symphony Evolution Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), MedImmune (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Symphony Evolution (Inst) Virote Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, AstraZeneca, Boehringer Ingelheim, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Lilly, Amgen, AstraZeneca, Sriuranpong Bristol-Myers Squibb, Eisai, Lilly, MSD Oncology, Eisai, MSD Oncology, Novartis, Roche MSD Oncology, -
Fidelity® Nasdaq Composite Index® Fund
Fidelity® Nasdaq Composite Index® Fund Semi-Annual Report May 31, 2021 Contents Note to Shareholders 3 Investment Summary 4 Schedule of Investments 6 Financial Statements 85 Notes to Financial 89 Statements Shareholder Expense 97 Example Board Approval of 98 Investment Advisory Contracts and Management Fees Liquidity Risk 106 Management Program To view a fund’s proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission’s (SEC) web site at http://www.sec.gov. You may also call 1-800-544-8544 to request a free copy of the proxy voting guidelines. Nasdaq®, OMX®, NASDAQ OMX®, Nasdaq Composite®, and The Nasdaq Stock Market®, Inc. are registered trademarks of The NASDAQ OMXGroup, Inc. (which with its Affiliates are the Corporations) and are licensed for use by Fidelity. The product has not been passed on by the Corporations as to its legality or suitability. The product is not issued, endorsed or sold by the Corporations. The Corporations make no warranties and bear no liability with respect to shares of the product. Standard & Poor’s, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation. Other third-party marks appearing herein are the property of their respective owners. All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2021 FMR LLC. All rights reserved. This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund. -
Next Generation Immuno-Oncology Targeting Hot and Cold Tumors
Next generation immuno-oncology targeting hot and cold tumors March 2017 iTeos – General Disclaimer Company Presentation “This presentation has been prepared by iTeos and is furnished to you by iTeos on a confidential basis and solely for your information. This presentation contains forward-looking statements, including (without limitation) statements concerning the progress and expectations of our (pre-)clinical pipeline and the financials of the company. When used in this presentation, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “will,” “plan,” “potential,” “possible,” “predict,” “objective,” “should,” and similar expressions are intended to identify forward- looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of iTeos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. All statements contained herein speak only as of the release date of this document. iTeos expressly disclaims any obligation to update any statement in this document to reflect any change or future development with respect thereto, any future results, or any change in events, conditions and/or circumstances on which any such statement is based, unless specifically required by law or regulation. Neither iTeos nor any of its officers, -
IGNYTE-ESO: a Master Protocol to Assess Safety and Activity of Letetresgene Autoleucel (Lete-Cel; GSK3377794) Victoria L
Sandra P. D’Angelo1, Jonathan Noujaim2, Fiona Thistlethwaite3, Albiruni R. Abdul Razak4, Silvia Stacchiotti5, Warren Chow6, John B.A.G. Haanen7, Anna Chalmers8, Steven I. Robinson9, Brian A. Van Tine10, Kristen N. Ganjoo11, Melissa L. Johnson12, 13 13 13 13 13 14 15 IGNYTE-ESO: a master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) Victoria L. Chiou , Thomas Faitg , Mary Woessner , Laura Pearce , Aiman Shalabi , Jean-Yves Blay , George D. Demetri 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Institut D’Hématologie-Oncologie, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; 3The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; 4Princess Margaret Cancer Centre and in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2) Mount Sinai Hospital, Toronto, ON, Canada; 5Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6City of Hope Comprehensive Cancer Center, Duarte, CA, United States; 7Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; 8Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 9Mayo Clinic, Rochester, MN, USA; 10Washington University in St. Louis, St. Louis, MO, USA; 11Stanford University Medical Center, Stanford, CA, USA; 12Sarah Cannon Research Institute, Nashville, TN, USA; 13GlaxoSmithKline, Philadelphia, PA, USA; Poster No. TPS11582 14Centre Léon Bérard, Lyon, France; 15Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA, USA Background Study design Study phases Unmet need IGNYTE-ESO (NCT03967223) is a master protocol that enables evaluation of multiple cell therapies Figure 3 displays the patient journey for both substudies, which includes leukapheresis for lete-cel manufacture, lymphodepletion chemotherapy, lete-cel infusion, and follow-up. -
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Author Manuscript Published OnlineFirst on December 1, 2017; DOI: 10.1158/2159-8290.CD-17-1009 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Genomic landscape of cell-free DNA in patients with colorectal cancer John H. Strickler1, Jonathan M. Loree2, Leanne G. Ahronian3, Aparna R. Parikh3, Donna Niedzwiecki1, Allan Andresson Lima Pereira2, Matthew Mckinney1, W. Michael Korn4,5, Chloe E. Atreya4, Kimberly C. Banks6, Rebecca J. Nagy6, Funda Meric-Bernstam2, Richard B. Lanman6, AmirAli Talasaz6, Igor F. Tsigelny7,8, Ryan B. Corcoran3 #, Scott Kopetz2 # 1Duke University Medical Center, Durham, NC, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA; 4Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; Caris Life Sciences, Phoenix, AZ, USA; 6Guardant Health, Inc., Redwood City, CA, USA; 7University of California San Diego, San Diego, CA, USA; 8CureMatch Inc., San Diego, CA, USA. #To whom correspondence should be addressed: Dr. Ryan B. Corcoran Massachusetts General Hospital Cancer Center, 149 13th St., 7th floor Boston, MA 02129 Phone: 617-726-8599 Fax: 617-724-9648 Email: [email protected] Dr. Scott Kopetz University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426 Houston, TX 77030 Phone: 713-792-2828 Fax: 713-563-2957 Email: [email protected] 1 Downloaded from cancerdiscovery.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 1, 2017; DOI: 10.1158/2159-8290.CD-17-1009 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. -
Feasibility and First Reports of the MATCH-R Repeated Biopsy Trial At
www.nature.com/npjprecisiononcology ARTICLE OPEN Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy Gonzalo Recondo 1, Linda Mahjoubi2, Aline Maillard3, Yohann Loriot1,4, Ludovic Bigot1, Francesco Facchinetti1, Rastislav Bahleda2, Anas Gazzah2, Antoine Hollebecque2, Laura Mezquita4, David Planchard1,4, Charles Naltet4, Pernelle Lavaud4, Ludovic Lacroix1,5,6, Catherine Richon5, Aurelie Abou Lovergne7, Thierry De Baere8, Lambros Tselikas8, Olivier Deas9, Claudio Nicotra2, Maud Ngo-Camus2, Rosa L. Frias1, Eric Solary10, Eric Angevin2, Alexander Eggermont4, Ken A. Olaussen1, Gilles Vassal7, Stefan Michiels 3, ✉ Fabrice Andre 1,4, Jean-Yves Scoazec5,6, Christophe Massard1,2, Jean-Charles Soria1,4, Benjamin Besse1,4 and Luc Friboulet 1 Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole 1234567890():,; exome sequencing. -
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20–F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ________________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number 000–26495 CYREN LTD. (Exact name of Registrant as specified in its charter and translation of Registrant’s name into English) Israel (Jurisdiction of incorporation or organization) 10 Ha-Menofim St, 5th Floor Herzliya 4672561, Israel 011–972–9–863–6888 (Address of principal executive offices) J. Michael Myshrall, Chief Financial Officer, 1430 Spring Hill Road Suite 330 McLean, VA 22102 Fax: 703-760-3321 (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Ordinary Shares, par value ILS 0.15 per share NASDAQ Capital Market Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report (December 31, 2017): 53,375,854 Ordinary Shares Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. -
Commtouch Software Ltd
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20–F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2011 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report…………. For the transition period from _________________ to ________________ Commission file number 000–26495 COMMTOUCH SOFTWARE LTD. (Exact name of Registrant as specified in its charter and translation of Registrant’s name into English) Israel (Jurisdiction of incorporation or organization) 4A Hazoran Street Poleg Industrial Park, P.O. Box 8511 Netanya 42504, Israel 011–972–9–863–6888 (Address of principal executive offices) Ron Ela, CFO, Fax: 011-972-9-8636863. Same address as above. (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Name of each exchange on which registered Ordinary Shares, par value NIS 0.15 per share NASDAQ Capital Market Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report (December 31, 2011). -
Elron Electronic Industries Ltd. (The “Company”) *** Shelf Prospectus
English Translation, for Convenience Purposes Only, of the Hebrew Shelf Prospectus submitted to the Israeli Securities Authority and Tel Aviv Stock Exchange Ltd. The following translation is intended solely for the convenience of the reader. This translation has no legal status and although every effort has been made to ensure its accuracy, the Company does not assume any responsibility whatsoever as to its accuracy and is not bound by its contents. Only the original Hebrew text is binding and reader is advised to consult the Hebrew text in all matters which may affect them. Elron Electronic Industries Ltd. (the “Company”) *** Shelf Prospectus According to this Shelf Prospectus, the Company may issue various types of securities according to the provisions of the law, including: shares, non-convertible debentures (including through the expansion of existing debentures series of the Company, as may be from time to time), debentures convertible into shares (including through the expansion of existing convertible debentures series, as may be from time to time), warrants exercisable into shares, warrants exercisable into non-convertible debentures, warrants exercisable into debentures that are convertible into shares, commercial securities and any other security which can lawfully be issued under a shelf prospectus on the relevant date (the "Offered Securities"). The offering of securities under this Shelf Prospectus shall be made pursuant to the provisions of Section 23A(f) of the Israel Securities Law 5728-1968, through shelf offering reports in which all the details specific to such offerings will be completed, including the details and terms and conditions of the securities and the composition of the offered units, according to the provisions of any law and according to the rules and guidelines of the Tel Aviv Stock Exchange Ltd., as they shall be at that time. -
Steady Course Or Changing Tides? 2015 Trial Starts 2016 Clinical Trials Roundup – Steady Course Or Changing Tides?
2016 Clinical Trials Roundup Steady course or changing tides? 2015 Trial Starts 2016 Clinical Trials Roundup – Steady course or changing tides? Welcome to this year’s roundup where we’ll review clinical trials that initiated in 2015 to elucidate any ongoing, or new, trends within the world of pharma R&D. Here we’ll provide a high-level overview of trial activity, focused on the six major therapeutic areas (TAs) of autoimmune/inflammation, cardiovascular, CNS, infectious disease, metabolic/endocrinology, and oncology, with metrics by TA, trial phase, and disease. We’ll then zoom in on the most active industry sponsors, including a closer look at how they may (or may not be) maximizing their assets. Now, let’s take a look at the new clinical research from 2015, and see how the course of pharma R&D fared. Doro Shin, MPH Principal Analyst, Infectious & Genitourinary Diseases Manager, Thought Leadership Program 2 April 2016 © Informa UK Ltd 2016 (Unauthorized photocopying prohibited.) Rounding up the 2015 debuts Similar to years past, this annual roundup will hone in on unapproved drug3 clinical research, which comprised Approximately 4,900 Phase I-III trials started in 2015 2,769 of trials starting in 2015 (57%). Involvement across the six TAs.1 Industry sponsors2 were involved from the industry is increased as 77% of trials initiated in the majority of these trials (2934 of 4895 trials, in 2015 with an unapproved drug is linked to an 60%), particularly in autoimmune research (487 of industry sponsor (2143 of 2769 trials). Again, 668 trials, 73%). Oncology had the lowest rate and autoimmune has the largest industry participation (383 just over half of cancer trials included an industry of 424 trials, 90%) while oncology has the lowest (750 sponsor (1110 of 2080 trials). -
Firstnet Interested Teaming/Partnering List
FirstNet Interested Teaming/Partnering List As a courtesy, FirstNet has maintained a list of vendors that are interested in subcontracting and partnering opportunities with other potential offerors on the Request for Proposals (RFP) for the FirstNet Network. The final day to get on this Teaming List was March 17, 2016. As of that date, FirstNet is no longer accepting submissions or edits to the below list. Offerors are not required to be on the Teaming List in order to submit a proposal to or to participate in the RFP. Being included on this list was optional and solely intended to be an avenue to facilitate potential subcontracting and partnering opportunities. FirstNet accepts no liability for any resultant outcomes. 21st Century Wireless Infrastructure; Applications; Devices; Towers/Sites; IT/Eng/Enterprise Services Stephen McKenna [email protected] (630) 546-3765 www.21stcenturytowers.com 21ST CENTURY TOWERS IS AVAILABLE TO PROVIDE SERVICES IN ALL 50 STATES. 21ST CENTURY WILL USE STANDARD TOWER AND CARRIER TECHNOLOGY. 21ST CENTURY TOWERS COMBINES: NEXT GENERATION OWNERSHIP MODELS; EXPERTISE IN TOWER MANAGEMENT, MAINTENANCE AND MODIFICIATIONS; ADVANCED FINANCIAL, LEASING AND OWNERSHIP MODELS; CUTTING EDGE POWER, COOLING / HEATING AND RELATED SOLUTIONS; OPERATIONAL AND FINANCIAL EXCELLENCE; EXPERIENCED MANAGEMENT; CLIENT-FOCUSED CULTURE; FINANCIAL STRENGTH 2pifi Infrastructure; Systems Integrator; Towers/Sites; IT/Eng/Enterprise services; Carrier: Custom transport or DIA links built to connect hard to reach sites anywhere in North America Andrew Kelly [email protected] (319) 248-0120 www.2pifi.com 2pifi is a last marathon connectivity provider covering all 50 states. 2pifi specializes in terrestrial microwave and fiber solutions 50mbps to 2gbps for hard to reach sites (sites that do not qualify for any traditional solution). -
Alphabetical Listing by Company Name: Number of Foreign
FOREIGN COMPANIES REGISTERED AND REPORTING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION December 31, 2014 Alphabetical Listing by Company Name COMPANY COUNTRY MARKET 21 Vianet Group Inc. Cayman Islands Global Market 500.com Ltd. Cayman Islands NYSE 51Job, Inc. Cayman Islands Global Market 58.com Inc. Cayman Islands NYSE ABB Ltd. Switzerland NYSE Abbey National Treasury Services plc United Kingdom NYSE - Debt Abengoa S.A. Spain Global Market Abengoa Yield Ltd. United Kingdom Global Market Acasti Pharma Inc. Canada Capital Market Acorn International, Inc. Cayman Islands NYSE Actions Semiconductor Co. Ltd. Cayman Islands Global Market Adecoagro S.A. Luxembourg NYSE Adherex Technologies Inc. Canada OTC Adira Energy Ltd. Canada OTC Administradora de Fondos de Pensiones-Provida, S.A. Chile OTC Advanced Semiconductor Engineering, Inc. Taiwan NYSE Advantage Oil & Gas Ltd. Canada NYSE Advantest Corp. Japan NYSE Aegean Marine Petroleum Network Inc. Marshall Islands NYSE AEGON N.V. Netherlands NYSE AerCap Holdings N.V. Netherlands NYSE Aeterna Zentaris Inc. Canada Capital Market Affimed N.V. Netherlands Global Market Agave Silver Corp. Canada OTC Agnico Eagle Mines Ltd. Canada NYSE Agria Corp. Cayman Islands NYSE Agrium Inc. Canada NYSE AirMedia Group Inc. Cayman Islands Global Market Aixtron SE Germany Global Market Alamos Gold Inc. Canada NYSE Alberta Star Development Corp. Canada OTC Alcatel-Lucent France NYSE Alcobra Ltd. Israel Global Market Alderon Iron Ore Corp. Canada NYSE MKT Alexco Resource Corp. Canada NYSE MKT Algae Dynamics Corp. Canada OTC Algonquin Power & Utilities Corp. Canada OTC Alibaba Group Holding Ltd. Cayman Islands NYSE Page 1 COMPANY COUNTRY MARKET Allot Communications Ltd. Israel Global Market Almaden Minerals Ltd.